The combination of PD-1 and PD-L1/PD-L2 can inhibit the activation of lymphocytes and the production of cytokines, leading to the deletion of tumor-infiltrating cells (TILs) and induction of immunological tolerance [8, 9]. Here, RPL17 is linked to neoplasm.